ABCG2 and cancer: Hence, inhibition of BPTF represses ABC-transporters, reducing gemcitabine efflux, and leading to its accumulation in cells, causing DNA damage and subsequently inducing programmed cell death [376, 379], demonstrating that combined BPTF-silencing and gemcitabine treatment can have complementary effects in treating MDR cancer [376].